184 related articles for article (PubMed ID: 9620047)
21. Fertility drug use and risk of ovarian tumors: a debated clinical challenge.
Gadducci A; Guerrieri ME; Genazzani AR
Gynecol Endocrinol; 2013 Jan; 29(1):30-5. PubMed ID: 22946709
[TBL] [Abstract][Full Text] [Related]
22. Effects of fertility drugs on cancers other than breast and gynecologic malignancies.
Brinton LA; Moghissi KS; Scoccia B; Lamb EJ; Trabert B; Niwa S; Ruggieri D; Westhoff CL
Fertil Steril; 2015 Oct; 104(4):980-988. PubMed ID: 26232746
[TBL] [Abstract][Full Text] [Related]
23. First-time postmenopausal bleeding as a clinical marker of long-term cancer risk: A Danish Nationwide Cohort Study.
Bengtsen MB; Veres K; Nørgaard M
Br J Cancer; 2020 Feb; 122(3):445-451. PubMed ID: 31806879
[TBL] [Abstract][Full Text] [Related]
24. Fertility drugs and cancer: a guideline.
;
Fertil Steril; 2016 Dec; 106(7):1617-1626. PubMed ID: 27573989
[TBL] [Abstract][Full Text] [Related]
25. Free androgen index and leptin are the most prominent endocrine predictors of ovarian response during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility.
Imani B; Eijkemans MJ; de Jong FH; Payne NN; Bouchard P; Giudice LC; Fauser BC
J Clin Endocrinol Metab; 2000 Feb; 85(2):676-82. PubMed ID: 10690875
[TBL] [Abstract][Full Text] [Related]
26. Italian cancer figures, report 2013: Multiple tumours.
AIRTUM Working Group
Epidemiol Prev; 2013; 37(4-5 Suppl 1):1-152. PubMed ID: 24259384
[TBL] [Abstract][Full Text] [Related]
27. Reproductive factors of ovarian and endometrial cancer risk in a high fertility population in Mexico.
Salazar-Martinez E; Lazcano-Ponce EC; Gonzalez Lira-Lira G; Escudero-De los Rios P; Salmeron-Castro J; Hernandez-Avila M
Cancer Res; 1999 Aug; 59(15):3658-62. PubMed ID: 10446978
[TBL] [Abstract][Full Text] [Related]
28. The possible association between IVF and breast cancer incidence.
Pappo I; Lerner-Geva L; Halevy A; Olmer L; Friedler S; Raziel A; Schachter M; Ron-El R
Ann Surg Oncol; 2008 Apr; 15(4):1048-55. PubMed ID: 18214616
[TBL] [Abstract][Full Text] [Related]
29. Assisted reproductive technology and the incidence of ovarian cancer: a meta-analysis.
Kashyap S; Moher D; Fung MF; Rosenwaks Z
Obstet Gynecol; 2004 Apr; 103(4):785-94. PubMed ID: 15051576
[TBL] [Abstract][Full Text] [Related]
30. Endometriosis and risks for ovarian, endometrial and breast cancers: A nationwide cohort study.
Mogensen JB; Kjær SK; Mellemkjær L; Jensen A
Gynecol Oncol; 2016 Oct; 143(1):87-92. PubMed ID: 27430396
[TBL] [Abstract][Full Text] [Related]
31. Risk of cancer among women with polycystic ovary syndrome: a Danish cohort study.
Gottschau M; Kjaer SK; Jensen A; Munk C; Mellemkjaer L
Gynecol Oncol; 2015 Jan; 136(1):99-103. PubMed ID: 25451694
[TBL] [Abstract][Full Text] [Related]
32. Risk for borderline ovarian tumours after exposure to fertility drugs: results of a population-based cohort study.
Bjørnholt SM; Kjaer SK; Nielsen TS; Jensen A
Hum Reprod; 2015 Jan; 30(1):222-31. PubMed ID: 25376453
[TBL] [Abstract][Full Text] [Related]
33. Reduced risk of breast and endometrial cancer among women with hip fractures (Sweden).
Persson I; Adami HO; McLaughlin JK; Naessén T; Fraumeni JF
Cancer Causes Control; 1994 Nov; 5(6):523-8. PubMed ID: 7827239
[TBL] [Abstract][Full Text] [Related]
34. The laparoscopic ovarian electrocautery versus gonadotropin therapy in infertile women with clomiphene citrate-resistant polycystic ovary syndrome; a randomized controlled trial.
Mehrabian F; Eessaei F
J Pak Med Assoc; 2012 Mar; 62(3 Suppl 2):S42-4. PubMed ID: 22768457
[TBL] [Abstract][Full Text] [Related]
35. Endometrial receptivity markers in infertile women stimulated with letrozole compared with clomiphene citrate and natural cycles.
Ganesh A; Chauhan N; Das S; Chakravarty B; Chaudhury K
Syst Biol Reprod Med; 2014 Apr; 60(2):105-11. PubMed ID: 24304327
[TBL] [Abstract][Full Text] [Related]
36. Breast cancer risk associated with ovulation-stimulating drugs.
Brinton LA; Scoccia B; Moghissi KS; Westhoff CL; Althuis MD; Mabie JE; Lamb EJ
Hum Reprod; 2004 Sep; 19(9):2005-13. PubMed ID: 15217997
[TBL] [Abstract][Full Text] [Related]
37. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial.
Anderson GL; Judd HL; Kaunitz AM; Barad DH; Beresford SA; Pettinger M; Liu J; McNeeley SG; Lopez AM;
JAMA; 2003 Oct; 290(13):1739-48. PubMed ID: 14519708
[TBL] [Abstract][Full Text] [Related]
38. Risks of ovarian, breast, and corpus uteri cancer in women treated with assisted reproductive technology in Great Britain, 1991-2010: data linkage study including 2.2 million person years of observation.
Williams CL; Jones ME; Swerdlow AJ; Botting BJ; Davies MC; Jacobs I; Bunch KJ; Murphy MFG; Sutcliffe AG
BMJ; 2018 Jul; 362():k2644. PubMed ID: 29997145
[TBL] [Abstract][Full Text] [Related]
39. Ovarian tumors in a cohort of infertile women.
Rossing MA; Daling JR; Weiss NS; Moore DE; Self SG
N Engl J Med; 1994 Sep; 331(12):771-6. PubMed ID: 8065405
[TBL] [Abstract][Full Text] [Related]
40. Cancer risk associated with subfertility and ovulation induction: a review.
Klip H; Burger CW; Kenemans P; van Leeuwen FE
Cancer Causes Control; 2000 Apr; 11(4):319-44. PubMed ID: 10843444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
